Who Should Take AMPYRA?
Is someone you care about living with multiple sclerosis (MS)?
AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
Not everyone responds to AMPYRA. Individual results may vary.
If your loved one could benefit from an improvement in walking related to their MS, you may want to encourage them to talk to their doctor about AMPYRA.
MS affects people's walking in different ways
There are many factors in determining if AMPYRA may be right for your loved one. It's important to understand how MS affects how they walk, and how this might affect their everyday life.
Learning their symptoms, how they start up, how often they occur, and if they're getting better or worse can all play key roles in helping their healthcare team decide if they should try AMPYRA.
It’s also important to know whether they have a history of seizures or have kidney problems or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA, since people with these conditions must not take AMPYRA.
Taking a walking self-assessment can help
Your loved one can use this tool to see how MS may be affecting their walking. All they have to do is answer a short list of questions and then discuss the results with their healthcare team.
Before you and your loved one talk to the doctor, you can create your own Talking to Your Doctor Discussion Guide. The Guide is free and can help you start the conversation with your healthcare provider about your loved one's walking.
AMPYRA Conversations
Watch a one-on-one interview with a family living with MS as they talk about signs a caregiver may notice and can help assess when it comes to observing changes in walking.
AMPYRA is indicated as a treatment to improve walking in patients with MS. AMPYRA improved walking in significantly more people with MS than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%). This was demonstrated by an increase in walking speed.
Not everyone responds to AMPYRA. Individual results may vary.
When you first noticed changes in Joy’s walking, what did you think?
Ben Bryant:Well, I notice that she slows down, or loses control of her speed altogether. And which, either one of those situations can be dangerous. Especially if we're in a crowd of people, or if there are obstacles in the way.
I remember vividly that I had to ask her, you know, "Let's take a break, let's stop." So that she can go ahead and regain control of her foot speed. Because, you know, it can be a dangerous issue, especially at a mall. And the last thing that I want her to do is to fall and hurt herself.
First Step
